Figure 1.

Adverse event rates of nasopharyngitis and upper respiratory tract infections in patients with inflammatory conditions on biologic therapies. Range of percentages reflects adverse event rates with increasing doses. Most biologics show no difference or a slight increase in rates of nasopharyngitis and upper respiratory tract infections compared to placebo. *Upper respiratory infection rates, including nasopharyngitis, upper respiratory tract infections, pharyngitis, and viral upper respiratory tract infections. **Pharyngitis rates. N/A, not available